Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Vioxx 12.5mg tablets
1001010AFBBACAC
|
Vioxx | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Vioxx 12.5mg/5ml oral suspension
1001010AFBBAAAA
|
Vioxx | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Vioxx 25mg tablets
1001010AFBBADAD
|
Vioxx | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Vioxx 25mg/5ml oral suspension
1001010AFBBABAB
|
Vioxx | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
VioxxAcute 25mg tablets
1001010AFBBAEAD
|
Vioxx | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
VioxxAcute 50mg tablets
1001010AFBBAFAE
|
Vioxx | Rofecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Volraman 25mg gastro-resistant tablets
1001010C0BFAAAD
|
Volraman | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Volraman 50mg gastro-resistant tablets
1001010C0BFABAE
|
Volraman | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Volsaid Retard 100 tablets
1001010C0BSABAF
|
Volsaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Volsaid Retard 75 tablets
1001010C0BSAAAL
|
Volsaid | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol 25mg gastro-resistant tablets
1001010C0BBAAAD
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol 50mg dispersible tablets
1001010C0BBAGAJ
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol 50mg gastro-resistant tablets
1001010C0BBABAE
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol 75mg SR tablets
1001010C0BBAHAL
|
Voltarol (Systemic) | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol Active 4% spray
1003020U0BIAAAH
|
Voltarol Active | Diclofenac sodium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol Joint Pain 12.5mg tablets
1001010AGBDAAAC
|
Voltarol Joint Pain | Diclofenac potassium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol Pain-eze 12.5mg tablets
1001010AGBCAAAC
|
Voltarol Pain-eze | Diclofenac potassium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol Pain-eze Extra Strength 25mg tablets
1001010AGBCABAA
|
Voltarol Pain-eze | Diclofenac potassium | Musculoskeletal and Joint Diseases | No data available |
|
Voltarol Rapid 25mg tablets
1001010AGBBAAAA
|
Voltarol Rapid | Diclofenac potassium | Musculoskeletal and Joint Diseases | No data available |
|
White liniment
1003020V0AAACAC
|
Generic embrocation | Turpentine oil | Musculoskeletal and Joint Diseases | No data available |
|
Xanthomax 100 tablets
1001040C0BJACAA
|
Xanthomax | Allopurinol | Musculoskeletal and Joint Diseases | No data available |
|
Xanthomax 300 tablets
1001040C0BJADAB
|
Xanthomax | Allopurinol | Musculoskeletal and Joint Diseases | No data available |
|
Xefo 4mg tablets
1001010AIBBABAB
|
Xefo | Lornoxicam | Musculoskeletal and Joint Diseases | No data available |
|
Xefo 8mg tablets
1001010AIBBACAC
|
Xefo | Lornoxicam | Musculoskeletal and Joint Diseases | No data available |
|
Xeljanz 10mg tablets
1001030ABBBABAC
|
Xeljanz | Tofacitinib | Musculoskeletal and Joint Diseases | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.